#USA #San Diego #ACA #Biolabs International #SpeedySwab®

Biolabs International Unveils an Innovative Test-to-Treat Solution

Introduction
In light of potential changes to the Affordable Care Act (ACA) that threaten healthcare coverage for millions of Americans, Biolabs International LLC has stepped up to introduce a groundbreaking solution: SpeedySwab®—an affordable, over-the-counter rapid testing system. This initiative is set to enhance healthcare accessibility during the busy respiratory illness season by connecting users directly with licensed telehealth providers.

Transforming Healthcare with SpeedySwab®
Launched on November 18, 2025, SpeedySwab® utilizes advanced AI-driven Computer Vision Machine Learning (CVML®) technology to streamline the at-home testing process. Patients can leverage this user-friendly tool to perform rapid respiratory tests, with results linked to healthcare professionals for timely medical guidance. This innovation marks a critical advancement in the push toward greater connectivity and efficiency within the healthcare sector as traditional in-person visits become increasingly burdensome and costly.

Gino Ajodani, the President of Biolabs International, emphasized the urgency of providing options that are not only dependable but also budget-friendly in a rapidly changing healthcare landscape. Initial trials of SpeedySwab® highlighted its potential, demonstrating a 68% decrease in overall care costs and a fourfold speed increase in accessing treatment.

The Necessity of Affordable Alternatives
As of early November 2025, many consumers face dwindling coverage options at the onset of flu season and amid the continuing pandemic. SpeedySwab® stands out as a practical alternative, underpinned by concrete performance metrics.

The average total care cost per episode utilizing SpeedySwab® is estimated at $51.46, factoring in a 2-pack test kit priced at $24.99 and various telehealth fees. Patients have two main telehealth options:

• - SYNC live provider visits at $59.95
• - ASYNC provider-reviewed submissions costing $29.95

Impressive Validation of SpeedySwab®

A recent pilot program that included 4,200 participants yielded remarkable satisfaction rates:

• - 93% found the SpeedySwab® process easier than traditional office visits.
• - 87% avoided unnecessary clinic or urgent care visits.
• - 91% expressed a willingness to use connected diagnostics in the future.

This streamlined approach not only reduces healthcare disparities but also enhances user experiences by minimizing the average time lost from work or school—only about 0.8 days per episode. As a result, the model has shown promising improvements, including a 51% boost in telehealth routing efficiency and an 89% digital activation rate for connected tests.

The Future of Healthcare Accessibility

Biolabs International’s innovative strategy also includes the robust application of CVML® technology, which interprets test results digitally to eliminate user error, ensuring consistent evaluations under standardized conditions. This is particularly crucial during the winter months when healthcare demands peak. With efforts focused on advanced health data reporting, Biolabs aims to facilitate secure communication with public health entities.

Reflecting on the transformative capabilities of SpeedySwab®, Ajodani conveyed confidence in the solution’s potential to redefine healthcare access. “As we navigate through uncharted coverage territory and rising costs, our test and its corresponding telehealth functionality ensure that healthcare remains readily accessible,” he remarked.

Looking Ahead

In an era characterized by rapid technological evolution, Biolabs International LLC aspires to channel its AI-driven technologies across a broader range of over-the-counter diagnostics. The ambition is clear: to constantly enhance accuracy, reduce human oversight, and ultimately provide timely, affordable healthcare solutions that can adapt to various testing requirements.

For more information about SpeedySwab® and its benefits, visit SpeedySwab.

About Biolabs International
Biolabs International (https://biolabsinternational.net/home) is a pioneering force in diagnostic innovations, aiming to broaden consumer access to cost-effective, convenient healthcare alternatives.

About Safe Health Systems
Safe Health Systems (https://www.safehealth.me) offers a compliant digital health platform, facilitating connected diagnostics and test-to-treat experiences for consumers.